YAP1 and gastric cancer: On the basis of the aforementioned information, we conducted a cascade of in vitro and in vivo assays based on the miR-365/TLR4/IRF3/YAP/CDX2 axis to identify novel biomarkers involved in GC tumor progression in order to improve the prognosis and further understand the exact molecular mechanism of GC.